Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 18, 2017 - Issue 1-2
Submit an article Journal homepage
18,499
Views
51
CrossRef citations to date
0
Altmetric
Research Article

Phase I clinical trial of safety of L-serine for ALS patients

Todd D. LevinePhoenix Neurological Associates, Phoenix, Arizona,
,
Robert G. MillerForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,
,
Walter G. BradleyDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, and Correspondence[email protected]
,
Dan H. MooreForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,
,
David S. SapersteinPhoenix Neurological Associates, Phoenix, Arizona,
,
Lynne E. FlynnPhoenix Neurological Associates, Phoenix, Arizona,
,
Jonathan S. KatzForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,
,
Dallas A. ForshewForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,
,
James S. MetcalfBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA
,
Sandra A. BanackBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA
&
Paul A. CoxBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA
 show all
Pages 107-111 | Received 23 May 2016, Accepted 03 Aug 2016, Published online: 02 Sep 2016

References

  • Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253–63.
  • DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.
  • Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci. 2011;124:225–50.
  • Metcalf JS, Banack SA, Lindsay J, Morrison LF, Cox PA, Codd GA. Co-occurrence of β-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990–2004. Environ Microbiol. 2008;10:702–8.
  • Bradley WG, Borenstein AR, Nelson LM, Codd GA, Rosen BH, Stommel EW, et al. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:325–33.
  • Tabatabaie L, Klomp LW, Berger R, de Koning TJ. L-serine synthesis in the central nervous system: a review of serine deficiency disorders. Mol Genet Metab. 2010;99:256–62.
  • Institute of Medicine (US). Panel on Micronutrients. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. Panel on Macronutrients Panel on the Definition of Dietary Fiber, Subcommittee on Upper Reference Levels of Nutrients, Subcommittee on Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. National Academies Press, 2005.
  • De Koning TJ. Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis. 2006;29:347–51.
  • Garofalo K, Penno A, Schmidt BP, Lee HJ, Frosch MP, von Eckardstein A, et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest. 2011;121:4735–45.
  • Dunlop RA, Cox PA, Banack SA, Rodgers KJ. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLos One. 2013;8:e75376.
  • Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc R Soc B. 2016;283:2015–397.
  • Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003;100:13380–3.
  • Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci USA. 2004;101:12228–31.
  • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
  • Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
  • Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007;6:1045–53.
  • Baumann F, Henderson RD, Morrison SC, Brown M, Hutchinson N, Douglas JA, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:194–202.
  • Berntzon L, Ronnevi LO, Bergman B, Eriksson J. Detection of BMAA in the human central nervous system. Neuroscience. 2015;292:137–47.
  • Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. Acta Neurol Scand. 2009;120:216–25.
  • Xie X, Basile M, Mash DC. Cerebral uptake and protein incorporation of cyanobacterial toxin β-N-methylamino-L-alanine. Neuroreport. 2013;24:779–84.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.